Professor and Chair of Urology, Sidney Kimmel Medical College of Thomas Jefferson University Senior Director for Clinical Affairs, Sidney Kimmel Cancer Center
Urology
Dr. Leonard G. Gomella, MD
|
|
Give Review
Leonard Gomella is an expert in the field of Urology. He went to medical school at University of Kentucky College of Medicine. University of Kentucky College of Medicine is ranked 63/72 in Research/PrimaryCare. He has 8 awards "Philadelphia Magazine", "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Men's Health", "Fellow (FACS)", "Super Doctor" and "Top MD". Leonard Gomella has written publications. He has 89 publications published with PubMed. The lastest paper is: 'Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs.' He is registered with Medicare and accepts Medicare payments.
Publications
- Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-Specific microRNAs.
- Novel actions of next-generation taxanes benefit advanced stages of prostate Cancer.
- Genomic prostate Cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.
- Recommendations for adjuvant post Prostatectomy radiation.
- Prostate Cancer: Alcohol, Cancer and 5α-reductase inhibitors-is there a link?
- Practical guide to immunotherapy in castration resistant prostate Cancer: the use of sipuleucel-T immunotherapy.
- Current management of advanced and castration resistant prostate Cancer.
- Prostate Cancer genomics: understanding the new landscape.
- Transrectal Prostate biopsy.
- Percutaneous cryoablation for recurrent low grade Renal cell carcinoma after failed nephron-sparing surgery.
- Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate Cancer.
- Prostate Cancer: a high value target for cost containment.
- Evolution of advanced technologies in prostate Cancer radiotherapy.
- Introduction: the changing landscape of prostate Cancer.
- Retropubic, laparoscopic, or robotic radical Prostatectomy: is there any real difference?
- STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression.
- Stereotactic body radiation therapy for prostate Cancer: is the technology ready to be the standard of care?
- Targeting cell cycle and hormone receptor pathways in Cancer.
- Actos, slings, finasteride, and the vaccine compensation solution.
- Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features: Comparative Analysis of Long-term Outcomes.
- CAUTI and Readmission Penalties: Urologists Beware.
- Contrast enhanced transrectal ultrasound for the detection of prostate Cancer: a randomized, double-blind trial of dutasteride pretreatment.
- Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
- Face, content, and construct validation of the da vinci skills simulator.
- The Quest for the Perfect Prostate Biopsy Continues.
- The effect of ethnicity and sexual preference on prostate-Cancer-related quality of life.
- Androgen deprivation therapy and competing risks.
- Traditional approaches to androgen deprivation therapy.
- Minimally invasive radical Prostatectomy: transition from pure laparoscopic to robotic-assisted radical Prostatectomy.
- The Prostate Cancer Unit: A Multidisciplinary Approach for Which the Time Has Arrived.
- Decorin antagonizes IGF-IR function by interfering with IGF-IR activity and attenuating downstream signaling.
- Androgen suppression strategies for prostate Cancer: is there an ideal approach?
- Physician Beliefs and Practices for Adjuvant and Salvage Radiation Therapy After Prostatectomy.
- Mitostatin is down-regulated in human prostate Cancer and suppresses the invasive phenotype of prostate Cancer cells.
- Enhancing prostate Cancer care through the multidisciplinary clinic approach: a 15-year experience.
- Preemptive multimodal pain regimen reduces opioid analgesia for patients undergoing robotic-assisted laparoscopic radical Prostatectomy.
- Enhanced transrectal ultrasound modalities in the diagnosis of prostate Cancer.
- The insulin-like growth factor receptor I promotes motility and invasion of Bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation...
- The quality-of-life impact of prostate Cancer treatments.
- Prevention of urinary Bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor.
- Transition from pure laparoscopic to robotic-assisted radical Prostatectomy: a single surgeon institutional evolution.
- Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate Cancer.
- Effect of percentage of positive Prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
- Current prostate Cancer treatments: effect on quality of life.
- Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy.
- Transperitoneal robotic-assisted laparoscopic Prostatectomy after prosthetic mesh herniorrhaphy.
- Proepithelin regulates prostate Cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.
- Percutaneous nephrostolithotomy--is it time to abandon extracorporeal shock wave lithotripsy?
- Effective testosterone suppression for prostate Cancer: is there a best castration therapy?
- Hand-assisted laparoscopic nephroureterectomy (HALNU): an assessment of the impact of obesity in 50 procedures.
- Contrast enhanced ultrasound flash replenishment method for directed Prostate biopsies.
- Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate Cancer detection and Gleason score.
- Micro-RNA profiling in kidney and Bladder cancers.
- Multi-institutional survey of laparoscopic ureterolysis for retroperitoneal fibrosis.
- Chromosomal deletions in Bladder cancer: shutting down pathways.
- Proepithelin promotes migration and invasion of 5637 Bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex.
- Hand-assisted laparoscopic ureterolysis to treat Ureteral obstruction secondary to idiopathic retroperitoneal fibrosis: assessment of a novel technique and initial ser...
- Targeting the genetic basis of transitional cell carcinoma.
- New imaging techniques in prostate Cancer.
- Outcomes of hand-assisted laparoscopic nephrectomy in technically challenging cases.
- Hand-assisted laparoscopic nephroureterectomy: analysis of distal ureterectomy technique, margin status, and surgical outcomes.
- Detection of Prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging.
- Effect of dutasteride therapy on Doppler US evaluation of Prostate: preliminary results.
- Quantitative computed tomography perfusion of prostate Cancer: correlation with whole-mount pathology.
- Circulating tumor cells predict survival in patients with metastatic prostate Cancer.
- Addressing the needs of the high-risk prostate Cancer patient.
- Chemoprevention using dutasteride: the REDUCE trial.
- New approaches to the minimally invasive treatment of Kidney tumors.
- Inactivation of the FHIT gene favors Bladder cancer development.
- Long-term outcome of patients with prostate Cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
- When prostate Cancer markers become unreliable: the PCPT dilemma.
- Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate Cancer.
- Hand assisted laparoscopic partial nephrectomy for peripheral and central lesions: a review of 30 consecutive cases.
- Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate Cancer.
- Perioperative morbidity of laparoscopic radical Prostatectomy compared with open radical retropubic Prostatectomy.
- Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate Cancer in patients undergoing surgical treatment for prostate Cancer.
- Pathologic comparison of laparoscopic versus open radical retropubic Prostatectomy specimens.
- Laparoscopy and urologic oncology--I now pronounce you man and wife.
- Radiation therapy after radical Prostatectomy: a review of the issues and options.
- Pseudomass of the Bladder neck after prostatectomy: report of two cases.
- Attitudes and use of complementary medicine in men with prostate Cancer.
- Prostate: high-frequency Doppler US imaging for Cancer detection.
- Directed biopsy during contrast-enhanced sonography of the Prostate.
- FEZ1/LZTS1 is down-regulated in high-grade Bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.
- High-frequency Doppler US of the Prostate: effect of patient position.
- Totally endoscopic management of upper Tract transitional-cell carcinoma.
- Contrast-enhanced US of the Prostate with Sonazoid: comparison with whole-mount Prostatectomy specimens in 12 patients.
- Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications.
Schools
University Of Kentucky
University Ky Med Center
National Canc Institute
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystometry
- Cystotomy
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Philadelphia Magazine
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Men's Health
- Fellow (FACS)
- Super Doctor
- Top MD
Education
-
University of Kentucky College of Medicine
Hospital
-
Thomas Jefferson University Hospital
Drug Facts
| NPI NUMBER | 1598781601 | |
| NPPES Provider LastName | GOMELLA | |
| NPPES Provider FirstName | LEONARD | |
| NPPES Provider ZIPCode | 191074414 | |
| NPPES Provider State | PA | |
| Specialty Description | Urology | |
| Total Claim Count | 163.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1598781601 |
| Last Name Of The Provider | GOMELLA |
| First Name Of The Provider | LEONARD |
| View All |
Similar Doctors
|
|
Douglas C. Kelly
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillip Abbosh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay Simhan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam C. Reese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nir Kleinmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei P. Tan, MD |
|
|
Dr. Jaber A. Alanzi, MD |
|
Dr. David J. Kraman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc A. Lavine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonard H. Finkelstein, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith N. Van Arsdalen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael J. Metro, MD
This Doctor is OpenDoctor Recommended.
|